
|Articles|February 28, 2022
Daily Medication Pearl: Alteplase (Activase)
Author(s)Saro Arakelians, PharmD
Alteplase (Activase) is indicated for the treatment of acute ischemic stroke, acute myocardial infarction, pulmonary embolism, and blocked central venous catheter.
Advertisement
Indication: Alteplase (Activase) is a tissue plasminogen activator indicated for the treatment of acute ischemic stroke, acute myocardial infarction to reduce mortality and incidence of heart failure, pulmonary embolism associated with low blood pressure, and blocked central venous catheter.
Insight:
- Dosing: The recommended dose is 0.9 mg/kg (not to exceed 90 mg total dose) infused intravenously over 60 minutes with 10% of the total dose administered as an initial bolus over 1 minute.
- Dosage forms: Lyophilized powder 50 mg and 100 mg with sterile water for injection USP for reconstitution at 1 mg per 1 mL.
- Adverse events: The most frequently occurring adverse reaction (> 5%) is bleeding.
- Mechanism of action: Alteplase is a serine protease responsible for fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin.
- Manufacturer: Genentech
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
FDA Approves Gazyva for Active Lupus Nephritis
3
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
4
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
5